# Thymosin Alpha-1 FAQ: Common Questions, Answered from the Record

> Thymosin Alpha-1 questions answered from the literature: what it is, what it does, whether it boosts immunity, how it differs from TB-500, its FDA status, and the doses studied — each cited.

Direct answers drawn from the published Thymosin Alpha-1 literature — definitional, comparative, regulatory and safety questions, each tied to the record.

## What is thymosin alpha 1?

Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated thymic polypeptide isolated from calf thymus (thymosin fraction 5); Goldstein and colleagues purified it and determined its complete amino-acid sequence in 1977 [1]. It is cleaved in the body from the precursor prothymosin alpha and acts as an immune modulator. The synthetic, sequence-identical drug form is called thymalfasin [4].

## What does thymosin alpha 1 do?

It tunes the immune system at the innate-adaptive interface. It signals through TLR2/TLR9 on dendritic cells to drive their maturation and antigen presentation, which matures T cells and promotes Th1 immunity, while a parallel IDO arm generates regulatory T cells [5]. The net effect studied is restoring depleted immunity while damping excessive inflammation. It does not build muscle.

## What is TA1 peptide?

TA1 peptide is shorthand for thymosin alpha-1 — the same 28-amino-acid acetylated thymic peptide [1]. The label is common in research-use settings. It is the endogenous molecule (or its identical synthetic form, thymalfasin), not a separate compound, and its activity depends on the acetyl cap on its N-terminus [1].

## Is TB-500 the same as thymosin alpha 1?

No. TB-500 refers to a fragment of thymosin beta-4, a 43-amino-acid actin-binding, tissue-repair peptide — a different molecule from thymosin alpha-1. Their immune effects can even be opposite: in the human mixed lymphocyte reaction, thymosin alpha-1 enhanced T-cell proliferative responses while thymosin beta-4 suppressed them [15]. Thymosin beta-4 is also the WADA-prohibited one.

## Thymosin alpha 1 vs thymosin beta 4 (TB-500) - what's the difference?

Different sequence, size, mechanism and use. Thymosin alpha-1 is a 28-amino-acid immunomodulatory peptide acting on dendritic cells and TLRs [5]; thymosin beta-4 (TB-500) is a 43-amino-acid actin-binding peptide with a tissue-repair role. In direct comparison they had opposing immunoregulatory effects on T-cell proliferation [15]. Only thymosin beta-4 is on the WADA Prohibited List.

## Where does thymosin alpha 1 come from in the body?

It is cleaved in vivo from a larger 113-amino-acid precursor protein called prothymosin alpha, and is associated with the thymus, where it was first isolated as part of thymosin fraction 5 [1]. Circulating levels decline with age and run lower in some chronic inflammatory and autoimmune conditions [16].

## Is thymosin alpha 1 a steroid?

No. It is a peptide — a short chain of 28 amino acids with an acetylated N-terminus [1]. Steroids are lipid molecules built on a different chemical scaffold and act through nuclear hormone receptors; thymosin alpha-1 works through cell-surface Toll-like receptors on immune cells [5]. The two are unrelated classes.

## Does thymosin alpha 1 boost the immune system?

The research describes it as restoring or modulating immune function rather than simply 'boosting' it. It matures dendritic cells and T cells and promotes Th1 responses, but it also activates a regulatory IDO arm that can damp inflammation [5]. In severe COVID-19 it raised T-cell numbers and reversed T-cell exhaustion in one cohort [6]. Effects vary by setting.

## What are the benefits of thymosin alpha 1?

The cited benefits are immune-restorative: increased intrahepatic NKT and cytotoxic T cells with virological response in a subset of chronic hepatitis B patients [8], reversal of T-cell exhaustion in severe COVID-19 [6], and use as an immune adjuvant abroad [4]. Anecdotally, people report fewer colds — but that is anecdotal, not clinical evidence.

## What is thymosin alpha 1 used for?

Abroad (as thymalfasin) it is used mainly for chronic hepatitis B and as an immune adjuvant, including in vaccine-augmentation and cancer-combination settings [4][7]. A reappraisal positions it as an immunostimulatory adjuvant alongside chemo- and immunotherapies in melanoma, hepatocellular carcinoma and lung cancer [7]. It is not approved for any use in the United States.

## Is thymosin alpha 1 FDA-approved?

No. Thymosin alpha-1 (thymalfasin) is not approved for marketing in the United States. It is approved in roughly 35 other countries for indications such as chronic hepatitis B and immune support [4]. In the US, availability is limited to investigational and compounding contexts; some historical orphan-drug designations existed but are not marketing approvals.

## Who should not take thymosin alpha 1?

The literature flags theoretical cautions rather than firm contraindications: people with established autoimmune disease (broadly enhancing effector immunity is a concern) [16] and solid-organ transplant recipients (it could work against intentional immunosuppression) [5]. Pregnancy and lactation safety data are absent [4]. These are mechanism-based cautions; no human trial has tested them directly.

## How long should you take thymosin alpha 1?

Trial durations varied by indication and are not a personal recommendation. Chronic hepatitis regimens ran for months (for example, 1.2 mg for 24 weeks) [8]; sepsis protocols ran five to seven days [2][3]; a comprehensive review describes single doses and 5-7-day multiple-dose regimens [4]. There is no established consumer course, and this site gives no dosing instructions.

## How long does it take for thymosin alpha 1 to work?

The literature does not define a consumer onset window. Pharmacologically the peptide clears the blood within about 24 hours, with a roughly 2-hour half-life [4], so its studied effects are attributed to the immune signaling it triggers rather than to sustained blood levels. Clinical endpoints in trials were measured over weeks to months [8].

## What is the dosing protocol for thymosin alpha 1?

Reported trial protocols, not recommendations: 1.6 mg subcutaneously twice weekly is the standard chronic-hepatitis regimen [4]; sepsis trials used 1.6 mg every 12 hours for 5-7 days [2][3]; COVID-19 cohorts used 1.6 mg daily [6]. A review describes a 0.8-6.4 mg single-dose range [4]. All figures are research data by population and route.

## How does thymosin alpha 1 make you feel?

As an immune modulator, most people report feeling little or nothing directly, since its effects are biochemical rather than sensory. Anecdotally, some describe feeling more resilient or recovering faster from illness; a minority report a brief flu-like or achy day or injection-site irritation. These are anecdotal reports, not clinical findings, and effects are not something most people perceive.

## How much thymosin alpha 1 should I take?

This site does not provide a dose. What the record contains are research figures by population and route: a 0.8-6.4 mg single-dose range and a 1.6 mg twice-weekly chronic regimen in published trials [4]. Those describe monitored clinical settings, not self-administration, and are not a recommendation for any individual.

## When is the best time to take thymosin alpha 1?

The literature does not establish a 'best time' for consumer use; trials administered it on fixed schedules tied to the indication — for example, twice weekly for chronic hepatitis or every 12 hours for several days in sepsis [3][4]. Because there is no approved US use and no consumer protocol, no timing guidance can be drawn from the record.

## Is thymosin alpha 1 safe to take?

In monitored clinical use abroad it has been well tolerated, with mild injection-site reactions the most common adverse effect across more than 600,000 surveilled patients and no documented organ toxicity at studied doses [17]. But it is not FDA-approved, research-grade material has no quality guarantees [4], and theoretical cautions apply in autoimmune disease and transplant [5][16]. Safety in trials is not the same as safety in unregulated self-use.

## Does thymosin alpha 1 help cancer?

It is studied as an adjuvant, not a standalone cancer treatment. A 2019 reappraisal frames it as an immunostimulatory add-on used with chemo- and immunotherapies in melanoma, hepatocellular carcinoma and lung cancer, possibly helping 'turn a cold tumour hot' and reducing checkpoint-inhibitor toxicity [7]. That is a research frame; it does not establish it as an approved cancer therapy.

## Is thymosin alpha 1 worth it?

That is a judgment the evidence only partly informs. The signal is strongest in chronic viral hepatitis and immune restoration [4][8]; it is genuinely mixed in COVID-19 and, critically, null in the largest sepsis trial (HR 0.99, P=0.93) [3]. With no US approval and quality uncertainty in research-grade supply [4], the record counsels tempered expectations, especially outside the indications where evidence is strongest.

## Does thymosin affect aging?

Endogenous thymosin alpha-1 levels decline with age, and vaccine-adjuvant research has explored countering age-related immune decline (immunosenescence) [16]. But the published record does not establish thymosin alpha-1 as an anti-aging treatment; the aging connection is about falling immune output over time, not a demonstrated longevity effect.

---

A register of record on the thymic immune peptide thymosin alpha-1 — every claim logged to its study, the largest sepsis trial's null result kept in plain view, and not one thing here a clinic, a prescription, or for sale.